Effect of Health Care Provider Delays on Short-Term Outcomes in Patients With Colorectal Cancer: Multicenter Population-Based Observational Study

Ahmed Abdulaal, Chanpreet Arhi, Paul ZiprinInteractive 2020 · DOI

Abstract

Diagnostic and treatment delays had no effect on the survival of this cohort of patients with CRC. The utility of the 2-week wait referral system is therefore questioned. Timely screening with subsequent early referral and access to diagnostics may have a more beneficial effect.

Introduction

Colorectal cancer (CRC) survival rates in the United Kingdom have historically lagged behind those of other European nations, despite comparable healthcare expenditures. This discrepancy has often been attributed to "provider delays"—the time elapsed during administrative and clinical processes within the National Health Service (NHS). To address this, the UK introduced the "2-week wait" (2WW) referral system, aiming to fast-track suspected cancer cases. However, the direct link between these specific wait times and patient mortality remains a subject of debate. This study investigates whether diagnostic and treatment intervals significantly impact short-term survival or if other factors, such as tumor biology and early detection via screening, play a more dominant role.

Methodology and Data Selection

This retrospective cohort study utilized data from the Somerset Cancer Register (SCR), tracking patients diagnosed with CRC between 2013 and 2016. A primary challenge in such studies is the "wait-time paradox," where clinicians prioritize the most symptomatic and advanced patients, potentially making shorter wait times appear correlated with higher mortality.

To mitigate this bias, the researchers applied rigorous exclusion criteria. Emergency admissions and patients with known metastatic disease at the time of diagnosis were excluded to ensure the cohort represented those whose outcomes might actually be influenced by provider delays. Furthermore, colon and rectal cancer cases were analyzed separately to account for their distinct clinical pathways, such as the frequent use of neoadjuvant therapy in rectal cancer.

Figure 3: Flowchart of patient selection and exclusion criteria used to establish the study cohort.

The final analysis included 648 patients (405 with colon cancer and 243 with rectal cancer) from an initial pool of over 5,000 suspected cases. Statistical methods included Cox proportional hazards regression and Kaplan-Meier survival analysis, with corrections for lead-time and immortal-time biases.

Defining Provider Delays

The study categorized delays into specific intervals to pinpoint where potential bottlenecks might affect outcomes. The diagnostic delay (T1) was defined as the time from the initial referral to the final diagnosis, while the treatment delay (T2) covered the period from diagnosis to the start of definitive treatment.

Figure 6: Schematic representation of the diagnostic (T1) and treatment (T2) time intervals analyzed in the study.

These intervals were further broken down into sub-intervals, such as the time from referral to the first hospital appointment (T1a) and the time from that appointment to the final diagnosis (T1c).

Key Findings

The results suggest a "neutrality of delay" for the majority of CRC patients. For colon cancer, no significant association was found between survival and either diagnostic delay ($P=.68$) or treatment delay ($P=.90$). The median diagnostic delay for both groups was 34 days.

In the rectal cancer cohort, while initial univariate analysis suggested a benefit to shorter diagnostic delays, this significance vanished upon more rigorous sensitivity analysis. However, a specific sub-interval in rectal cancer—the time between the first hospital appointment and diagnosis (T1c)—was significantly associated with worse survival ($P=.048$). This likely reflects the complexity of staging rectal tumors and the impact of delays during this critical clinical phase.

Discussion and Conclusion

These findings challenge the prevailing clinical focus on the "2-week wait" target as the primary metric for improving cancer outcomes. While the 2WW system serves as an essential triage tool, administrative speed within the provider system appears less critical than "patient delay" (the time before seeking medical advice) and the stage of disease at presentation.

The study concludes that while provider delays should be minimized for patient experience and efficiency, they may not be the "silver bullet" for increasing survival rates. Instead, efforts should be directed toward enhancing screening programs, which facilitate earlier detection and referral, and optimizing complex diagnostic pathways for specific cases like rectal cancer. Future research should focus on the quality and nature of diagnostic interventions rather than solely on the duration of the wait.

Summary updated

Abstract

Diagnostic and treatment delays had no effect on the survival of this cohort of patients with CRC. The utility of the 2-week wait referral system is therefore questioned. Timely screening with subsequent early referral and access to diagnostics may have a more beneficial effect.
BibTeX
@inproceedings{abdulaal2020effect,
  author = {Ahmed Abdulaal and Chanpreet Arhi and Paul Ziprin},
  title = {{Effect of Health Care Provider Delays on Short-Term Outcomes in Patients With Colorectal Cancer: Multicenter Population-Based Observational Study}},
  booktitle = {Interactive},
  year = {2020},
  doi = {10.2196/15911},
}
Figure